A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know – Image for illustrative purposes only (Image credits: Unsplash)
Medicare beneficiaries facing obesity could soon fill prescriptions for popular GLP-1 drugs like Wegovy and Zepbound at just $50 a month. The Centers for Medicare & Medicaid Services announced a pilot program that marks a significant departure from longstanding restrictions on covering weight loss treatments. Set to launch on July 1, 2026, this initiative aims to address affordability barriers for medications that have transformed weight management but remained out of reach for many without insurance support.
A Pilot Program Reshaping Access to Obesity Treatments
The Medicare GLP-1 Bridge program represents a temporary but targeted expansion of coverage. It will operate from July 1, 2026, through December 31, 2027, serving as a stopgap before any potential permanent changes in 2028. CMS designed it to cover specific GLP-1 formulations approved for weight loss, including injectable and pill versions of Wegovy, the KwikPen version of Zepbound, and the Foundayo pill.
Unlike standard Medicare benefits, this pilot routes prescriptions through a centralized prior authorization system managed by contractor Humana. Physicians submit requests regardless of their Medicare provider status, and approved patients pick up medications at pharmacies with the fixed $50 copayment. The structure bypasses traditional Part D plans, creating a streamlined but distinct pathway.
Eligibility Criteria Target Those with Elevated Health Risks
Participation requires enrollment in a Medicare Part D prescription drug plan, followed by meeting clinical thresholds. Beneficiaries qualify with a body mass index of 35 or higher, or a BMI of 27 or above paired with conditions like heart disease or prediabetes. These standards align with clinical guidelines for obesity interventions, affecting a substantial portion of older adults – about 40% of American adults exceed a BMI of 30, per Centers for Disease Control and Prevention data.
For those already using GLP-1s for weight loss, prescribers must confirm initial eligibility in the prior authorization. A patient who began therapy with a qualifying BMI retains access even if weight loss lowers it later. However, the program applies solely to weight loss prescriptions; coverage for diabetes, cardiovascular risk, or sleep apnea continues through regular Part D channels.
Comparing Costs: From Hundreds to a Flat $50 Fee
The program’s appeal lies in its predictable pricing amid otherwise steep expenses. Without coverage, discounted cash prices via platforms like TrumpRx range widely based on dosage and formulation. Higher doses, often needed for sustained results, push costs even further.
| Medication | Typical Discounted Monthly Cost (Higher Dose) | Bridge Program Copay |
|---|---|---|
| Wegovy (injectable) | $399 | $50 |
| Zepbound (KwikPen) | $699 | $50 |
| Wegovy (pill) | $299 | $50 |
| Foundayo (pill) | $349 | $50 |
This flat rate offers relief, particularly as half of GLP-1 users reported affordability struggles in KFF polling, with a quarter calling it very difficult. Yet the copay carries limitations: it does not apply toward Part D deductibles or the $2,100 annual out-of-pocket maximum.
Key Hurdles and the Uncertain Path Ahead
Low-income beneficiaries face additional barriers. Those in the Medicare Extra Help program cannot combine its subsidies with Bridge coverage, potentially making $50 per month feel burdensome for individuals on fixed incomes like Social Security. “Fifty dollars a month sounds like a great deal compared to paying the discounted prices… but it’s a lot of money for somebody who’s living on a $750-a-month Social Security check,” noted Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF.
Studies indicate weight regain often follows discontinuation, and the pilot’s end date looms in late 2027. Originally shorter, CMS extended it after insurers declined a voluntary long-term arrangement that would have shifted costs. The extension provides data for negotiations but raises spending concerns. “This will just cost additional money, and we don’t know how much,” Cubanski observed, with potential billions in annual Medicare outlays depending on uptake among the estimated 14 million overweight or obese beneficiaries.
As the program nears, it underscores a pivotal moment in addressing obesity among older Americans. While not a full solution, the Bridge offers a foothold for accessible treatment, prompting questions about sustainability and broader reforms. For details, see the original reporting by KFF Health News.
